Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells.

Trial Profile

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Fludarabine (Primary) ; Cyclophosphamide
  • Indications Aplastic anaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jul 2017 Planned End Date changed from 30 Jun 2017 to 30 Jun 2018.
    • 06 Jul 2017 Planned primary completion date changed from 30 Jun 2017 to 30 Jun 2018.
    • 27 Apr 2016 Planned number of patients changed from 110 to 95.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top